PRWeb The Leader Press Release Distribution

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for December 21, 2004 Subscribe to this News Feed    
 

Beasley Allen Law Firm Calls Upon Pfizer for Celebrex Recall

Experienced Celebrex attorneys have been reviewing patient cases against Pfizer since 2000.

Montgomery, AL (PRWEB) December 21, 2004 -- Tom Methvin, managing shareholder at Beasley Allen Law Firm, has called upon Pfizer to recall Celebrex. Our firm has been watching the situation unfold over the past 4 years. In light of the recent findings which undeniably link Celebrex to greater heart-attack risks, it is time for Pfizer to act responsibly and pull the drug from the market," said Mr. Methvin at a recent press conference.

Celebrex-Lawsuit-x220.jpg

Mr. Methvin said, and I believe they are making a careless decision in not doing so immediately.
According to a clinical trial conducted by the National Cancer Institute (NCI) and Pfizer, Inc., patients taking 400 mg of the drug twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo. For patients in the trial taking 200 mg. twice daily, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.

These findings are similar to recent results from a study of Vioxx (rofecoxib), another drug in the same class. Vioxx was recently voluntarily recalled by Merck in September. Another drug in this class, Bextra (valdecoxib) has shown an increased risk for CV events in patients after heart surgery. Bextra and Celebrex are the only two selective COX-2 agents currently on the U.S. market.

While Pfizer announced today that it would halt advertising of the drug, it appears they had little choice in that decision. The Food and Drug Administration said on Friday that it was considering regulatory measures that could include severe label warnings or even requiring that the drug be withdrawn in the United States.

Pfizer will inevitably have to recall Celebrex," Mr. Methvin said, and I believe they are making a careless decision in not doing so immediately."

Andy Birchfield, Beasley Allens lead Celebrex Litigation attorney, is spearheading the review of 383 cases, having filed 53 of those cases against Pfizer dating back to 2000.

For more information:
Andy Birchfield, Attorney
Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
1-800-898-2034 toll free
1-334-954-7555 fax
andy.birchfield@beasleyallen.com

Online Media Contact:
Jayme Yarroch
1-800-898-2343 toll free
1-334-657-8959 mobile
jayme.yarroch@beasleyallen.com
Beasley Allen Law Firm
Celebrex Lawsuit Information

# # #

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Andy Birchfield
Beasley Allen Law Firm
1-800-898-2034
Email us Here
ATTACHED FILES

Celebrex Legal Information Screen Shot

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appearshere.
 
Close Move